drugset / Trial / NCT04840394
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Timeline
- Start
- 2021-06-22
- Primary completion
- 2024-03-31
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BDB018 | Unknown | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.